Seattle genetics announces positive topline results from trial of tucatinib in locally advanced or metastatic her2-positive breast cancer

Seattle genetics announces positive topline results from pivotal trial of tucatinib in locally advanced or metastatic her2-positive breast cancer.seattle genetics - her2climb trial met primary endpoint and both key secondary endpoints.seattle genetics -regulatory strategy for tucatinib includes nda submission to u.s. fda planned for q1 2020.seattle genetics - tucatinib in combination with trastuzumab & capecitabine was generally well tolerated with manageable safety profile.
SGEN Ratings Summary
SGEN Quant Ranking